174 related articles for article (PubMed ID: 12861629)
1. Correlation of matrix metalloproteinase-2, -9, tissue inhibitor-1 of matrix metalloproteinase and CD44 variant 6 in head and neck cancer metastasis.
Xu YP; Zhao XQ; Sommer K; Moubayed P
J Zhejiang Univ Sci; 2003; 4(4):491-501. PubMed ID: 12861629
[TBL] [Abstract][Full Text] [Related]
2. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma.
Zhang S; Li L; Lin JY; Lin H
World J Gastroenterol; 2003 May; 9(5):899-904. PubMed ID: 12717827
[TBL] [Abstract][Full Text] [Related]
3. Expression and correlation of CD44v6, vascular endothelial growth factor, matrix metalloproteinase-2, and matrix metalloproteinase-9 in Krukenberg tumor.
Lou G; Gao Y; Ning XM; Zhang QF
World J Gastroenterol; 2005 Aug; 11(32):5032-6. PubMed ID: 16124061
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of MMP-2, -9 and TIMP-1,-2 immunoreactive protein at the invasive front in advanced head and neck squamous cell carcinomas.
Ondruschka C; Buhtz P; Motsch C; Freigang B; Schneider-Stock R; Roessner A; Boltze C
Pathol Res Pract; 2002; 198(8):509-15. PubMed ID: 12389993
[TBL] [Abstract][Full Text] [Related]
5. Imbalance between Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases Promotes Invasion and Metastasis of Head and Neck Squamous Cell Carcinoma.
Stanciu AE; Zamfir-Chiru-Anton A; Stanciu MM; Popescu CR; Gheorghe DC
Clin Lab; 2017 Oct; 63(10):1613-1620. PubMed ID: 29035450
[TBL] [Abstract][Full Text] [Related]
6. Prognostic molecular markers in head and neck squamous cell carcinoma in a New Zealand population: matrix metalloproteinase-2 and sialyl Lewis x antigen.
Gunawardena I; Arendse M; Jameson MB; Plank LD; Gregor RT
ANZ J Surg; 2015 Nov; 85(11):843-8. PubMed ID: 24171785
[TBL] [Abstract][Full Text] [Related]
7. [Effects of ru'ai shuhou recipe on the matrix metalloproteinases and the inhibitive factors in the recurrence and metastasis of HER2 positive breast cancer].
Wu XQ; Shao SJ; Qu WC
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Nov; 32(11):1526-30. PubMed ID: 23359979
[TBL] [Abstract][Full Text] [Related]
8. MMP-2, TIMP-2 and CD44v6 expression in non-small-cell lung carcinomas.
Eren B; Sar M; Oz B; Dincbas FH
Ann Acad Med Singap; 2008 Jan; 37(1):32-9. PubMed ID: 18265895
[TBL] [Abstract][Full Text] [Related]
9. [Expression and significance of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase in non-melanoma skin cancer].
Fu XR; Zhang C; Chen CY; Zhang L; Wang LX; Wang BH; Liu XY; Zhang MZ
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):369-73. PubMed ID: 22883459
[TBL] [Abstract][Full Text] [Related]
10. Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer.
Zhang B; Cao X; Liu Y; Cao W; Zhang F; Zhang S; Li H; Ning L; Fu L; Niu Y; Niu R; Sun B; Hao X
BMC Cancer; 2008 Mar; 8():83. PubMed ID: 18373849
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Influence of Tumor Stroma on Breast Cancer Subtypes.
Cid S; Eiro N; Fernández B; Sánchez R; Andicoechea A; Fernández-Muñiz PI; González LO; Vizoso FJ
Clin Breast Cancer; 2018 Feb; 18(1):e123-e133. PubMed ID: 28927692
[TBL] [Abstract][Full Text] [Related]
12. Tumoral and stromal expression of MMP-2, MMP-9, MMP-14, TIMP-1, TIMP-2, and VEGF-A in cervical cancer patient survival: a competing risk analysis.
Azevedo Martins JM; Rabelo-Santos SH; do Amaral Westin MC; Zeferino LC
BMC Cancer; 2020 Jul; 20(1):660. PubMed ID: 32669083
[TBL] [Abstract][Full Text] [Related]
13. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
14. Tumor progression driven by pathways activating matrix metalloproteinases and their inhibitors.
Bodnar M; Szylberg Ł; Kazmierczak W; Marszalek A
J Oral Pathol Med; 2015 Jul; 44(6):437-43. PubMed ID: 25244188
[TBL] [Abstract][Full Text] [Related]
15. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas.
Maeta H; Ohgi S; Terada T
Virchows Arch; 2001 Feb; 438(2):121-8. PubMed ID: 11253113
[TBL] [Abstract][Full Text] [Related]
16. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck.
Franchi A; Santucci M; Masini E; Sardi I; Paglierani M; Gallo O
Cancer; 2002 Nov; 95(9):1902-10. PubMed ID: 12404284
[TBL] [Abstract][Full Text] [Related]
17. Plasma level of tissue inhibitor of matrix metalloproteinase-1 but not that of matrix metalloproteinase-8 predicts survival in head and neck squamous cell cancer.
Pradhan-Palikhe P; Vesterinen T; Tarkkanen J; Leivo I; Sorsa T; Salo T; Mattila PS
Oral Oncol; 2010 Jul; 46(7):514-8. PubMed ID: 20371206
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase-9 as a potential tumor marker in breast cancer.
Nanda DP; Sil H; Moulik S; Biswas J; Mandal SS; Chatterjee A
J Environ Pathol Toxicol Oncol; 2013; 32(2):115-29. PubMed ID: 24099425
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
[TBL] [Abstract][Full Text] [Related]
20. Expression and Concentration of Matrix Metalloproteinase 9 and Tissue Inhibitor of Matrix Metalloproteinases 1 in Laryngeal Squamous Cell Carcinoma.
Matulka M; Konopka A; Mroczko B; Pryczynicz A; Kemona A; Groblewska M; Sieskiewicz A; Olszewska E
Dis Markers; 2019; 2019():3136792. PubMed ID: 31143300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
